Slide 1: Courageous Innovation
——— ~ ocugen. ee Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies, Cell Therapies, and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally BIO June 16,2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical
Slide 3: We're Here to Make an Impact Through Courageous Innovation
We’re Here to Make an Impact Through Courageous Innovation Company Overview Head Office & Cell & Gene Manufacturing Malvern, PA Ticker Symbol OCGN India Business Center Hyderabad Our Values Respect Integrity Teamwork Accountability ones ocugen. —
Slide 4: Targeting Three Biologics License Applications (BLAs) in Three Years
Targeting Three Biologics License Applications (BLAs) in Three Years U.S./EU T: t BLA/MAA Product Candidate Status pete ee EGE / OcU400 Phase 3 in Progress Retinitis Pigmentosa (RP) (Largest Orphan Gene Therapy 300,000 2026 (Gene-agnostic targeting Clinical Trial) >100 genes, broad indication) OCU41
Slide 5: Modifier Gene Therapy Platform
Modifier Gene Therapy Platform Breakthrough technology designed to address many rare diseases as well as complex diseases that affect millions — ocugen. —
Slide 6: The Photoreceptor is Dependent on Cellular Homeostasis Regulated by Key Transcription Factors
The Photoreceptor is Dependent on Cellular Homeostasis Regulated by Key Transcription Factors (TFs) such as NR2E3 (OCU400) Untreated — RP T -OCU4 (Rho mutation) reated -OCU400 Os ONL INL Recovery after treatment with OCU400 RP Impact on the Photoreceptor Normal Photoreceptor * Immunolabeling of rod
Slide 7: OCU400 for Retinitis Pigmentosa
OCU400 for Retinitis Pigmentosa
Slide 8: OCU400 First-in-Class Novel Modifier Gene Therapy for RP
OCU400 First-in-Class Novel Modifier Gene Therapy for RP Unmet Need ~300,000 people in the U.S./EU and 1.6 million globally suffer from RP, which affects >100 genes OCU400 Market Potential—U.S. & EU Luxturna peak annual sales $52M* (2023) with a patient population of ~2,000 One approved product (Lux
Slide 9: Visual Field Proportion of Responders
Visual Field 0 10 20 30 40 50 60 70 80 P ro p o rt io n o f R e s p o n d e rs 75% 6/8
Slide 10: Mean Change in LLVA from Baseline
• • • o ± Year 1 Year 2 -5 0 5 10 M e a n Δ L L V A ( ± S E M ) fr o m B a s e li n e Treated Eye Untreated Eye * p = 0.005 p = 0.021 * Year 1 Year 2 -5 0 5 10 M e a n Δ L L V A ( ± S E M ) fr o m B a s e li n e Treated Eye Untreated Eye * p = 0.005 p = 0.055
Slide 11: OCU410ST for Stargardt Disease
OCU410ST for Stargardt Disease
Slide 12: OCU410ST First-in-Class Novel Modifier Gene Therapy Product for Stargardt Disease
OCU410ST First-in-Class Novel Modifier Gene Therapy Product for Stargardt Disease Unmet Need ~100,000 Patients in U.S./EU and 1 million globally who suffer from ABCA4- OCU410ST Market Potential associated retinopathies' (>1,200 mutations) Currently there are no approved products in the market and it
Slide 13: Mean Change in Total Atrophy Area and BCVA
0.0 0.5 1.0 1.5 12MM e a n C h a n g e ( ± S E M ) i n T o ta l A tr o p h y A re a f ro m B a s e li n e ( m m 2 ) Treated Eye Untreated Eye Baseline M3 M6 M12 -10 -5 0 5 10 M e a n C h a n g e i n B C V A (E T D R S ) fr o m B a s e li n e ( ± S E M ) Treated Eye Untreated Eye • • ± ± ± ± ± ± ±
Slide 14: Phase 2/3 Pivotal Confirmatory Trial
Phase 2/3 Pivotal Confirmatory Trial D established from ise 1 trial Randomization 2:1 Control 4-weekdata review of first 17 subjects 4-weekdata review of next17_ subjects: 4-weekdata review of all St subjects Phase 2/3 Dose Vg/ml Control Group No treatment | Treatment Group 1.5*10" vg/mL_ — ocugen.
Slide 15: OCU410 for Geographic Atrophy
OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Slide 16: OCU410 First-in-Class Novel Modifier Gene Therapy for GA
OCU410 First-in-Class Novel Modifier Gene Therapy for GA Unmet Need ~19 million people in U.S. and EU and 260 million globally suffer from dAMD" ~2-3 million people in U.S. & EU suffer from GA—advanced dAMD? Currently, approved products target only one disease pathway associated with GA and address
Slide 17: Mean Change in LLVA from Baseline
• • BL 3M 6M 9M 12M -25 -20 -15 -10 -5 0 5 10 M e a n c h a n g e i n L L V A (E T D R S ) fr o m B a s e li n e Treated Eye Untreated Eye ±
Slide 18: OCU410 Phase 1—Tissue Preservation Compared to Current Treatments
OCU410 Phase 1—Tissue Preservation Compared to Current Treatments 08 rr 07 H H t ' § H H sgo° H H OE 1 I Sos i : li eral a8 ‘ Single sub-retinal injection of 23 o8 OCU410 at 12M is more effective gs 03 when compared to PM and PEOM ce ie treatment £ = 22 0.4 0.76 go Ta) PEOM (12M) PM (12M) OCU410(12M
Slide 19: Patient Learned of OCU410ST Clinical Trial
PATIENT LEARNED OF OCU410ST CLINICAL TRIAL OCU410ST is an investigational drug product Ocugen is researching for the treatment of certain patients with Stargardt Disease. OCU410ST has not been determined to be safe and/or effective and is not currently approved for any use.
Slide 20: Ocugen Vision
Ocugen” Vision Fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation [eN — ocugen. 20 —